Juli Plc recorded a 45.5% decline in revenue to ₦146.86 million in the first half of 2026, from ₦269.25 million reported in the corresponding period of 2025.
Despite the sharp decline in turnover, the company narrowed its loss for the six-month period to ₦12.86 million, compared with a loss of ₦31.54 million in H1 2025.
The company disclosed the figures in its second-quarter financial statements for the period ended June 30, 2026.
Juli Plc’s turnover declined from ₦269.25 million in H1 2025 to ₦146.86 million in H1 2026, representing a 45.5% year-on-year contraction.
The decline was accompanied by a reduction in cost of sales, which fell to ₦98.14 million from ₦180.12 million.
Consequently, gross profit declined to ₦48.72 million from ₦89.13 million in the previous corresponding period.
Pharmaceuticals remained the company’s largest revenue contributor during the quarter, generating ₦59.80 million, compared with ₦111.13 million in Q2 2025.
Household and consumer goods contributed ₦6.28 million, down from ₦10.52 million, while laboratory revenue fell to ₦1.89 million from ₦7.70 million.
Juli Plc reduced its six-month loss to ₦12.86 million from ₦31.54 million in H1 2025.
The improvement came despite the significant revenue contraction, as total administrative expenses declined to ₦61.58 million from ₦120.67 million.
